Ausgabe 2/2019
Inhalt (16 Artikel)
APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?
Tatsuo Kanda, George K. K. Lau, Lai Wei, Mitsuhiko Moriyama, Ming-Lung Yu, Wang-Long Chuang, Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Jose Sollano, Manoj Kumar, Ankur Jindal, Barjesh Chander Sharma, Saeed S. Hamid, A. Kadir Dokmeci, Mamun-Al-Mahtab, Geofferey W. McCaughan, Jafri Wasim, Darrell H. G. Crawford, Jia-Horng Kao, Osamu Yokosuka, Shiv Kumar Sarin, Masao Omata
Serum ferritin as a biomarker for NAFLD: ready for prime time?
Raj A. Shah, Kris V. Kowdley
Immunological cure of HBV infection
Julia Lang, Christoph Neumann-Haefelin, Robert Thimme
Laser capture microdissection: techniques and applications in liver diseases
Beatriz Aguilar-Bravo, Pau Sancho-Bru
Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection
Lung-Yi Mak, Danny Ka-Ho Wong, Wai-Kay Seto, Qin Ning, Ka-Shing Cheung, James Fung, Ching-Lung Lai, Man-Fung Yuen
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
Amr Shaaban Hanafy, Mohamed A. Bassiony, Mohammad Abd Alkhalik Basha
Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India
Ajit Sood, Ajay Duseja, Mayank Kabrawala, Pradeep Amrose, Bhadadev Goswami, Abhijit Chowdhury, Shiv Kumar Sarin, Abraham Koshy, Robert H. Hyland, Sophia Lu, Gregory Camus, Luisa M. Stamm, Diana M. Brainard, G. Mani Subramanian, Madhura Prasad, Shobna Bhatia, Samir R. Shah, Dharmesh Kapoor, Shalimar, Vivek Saraswat
Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms
Ye Jin, Zhi-Yong Liang, Wei-Xun Zhou, Li Zhou
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
Ashokkumar Jain, Danielle Miller, Ian Schreibman, Thomas R. Riley III, Karen L. Krok, Takehiko Dohi, Rajeev Sharma, Zakiyah Kadry
The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
Shuntaro Obi, Takahisa Sato, Shinpei Sato, Miho Kanda, Yuta Tokudome, Yuichiro Kojima, Yoji Suzuki, Kenji Hosoda, Toshihiro Kawai, Yuji Kondo, Yoshihiro Isomura, Hiroshi Ohyama, Keiko Nakagomi, Hiroshi Ashizawa, Yuko Miura, Hiroyuki Amano, Hitoshi Mochizuki, Masao Omata
Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016
Donghee Kim, Won Kim, Adeyinka C. Adejumo, George Cholankeril, Sean P. Tighe, Robert J. Wong, Stevan A. Gonzalez, Stephen A. Harrison, Zobair M. Younossi, Aijaz Ahmed
Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd–Chiari syndrome on warfarin
Akash Shukla, Abhinav Jain, Vinit Kahalekar, Sheetal Bendkhale, Nithya Gogtay, Urmila Thatte, Shobna Bhatia
Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population
Ju Young Jung, Jae-Jun Shim, Sung Keun Park, Jae-Hong Ryoo, Joong-Myung Choi, In-Hwan Oh, Kyu-Won Jung, Hyunsoon Cho, Moran Ki, Young-Joo Won, Chang-Mo Oh
Influence of proton pump inhibitors on microbiota in chronic liver disease patients
Kenta Yamamoto, Masatoshi Ishigami, Takashi Honda, Tomoaki Takeyama, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Kazuhiko Hayashi, Hidemi Goto, Yoshiki Hirooka